Effect of Low-Calorie Diet and Lifestyle Intervention on Reversal of T2DM
NCT ID: NCT05925946
Last Updated: 2023-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
60 participants
INTERVENTIONAL
2023-10-01
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Group
1. Phase1 (Partial diet replacement) (850 Kcal/day) (12-20 weeks)):
2. Phase 2 (Gradual increase in calories) (20-28 weeks) (1100 Kcal/day):
3. Phase 3 (Weight loss maintenance) (29-104 weeks) (up to 1200Kcal/day) :
CURE-DM
1. This randomized controlled prospective trial will be of 2 years duration where 150 patients with T2DM from urban areas of Delhi will be screened.
2. These subjects will be randomized into two groups by computer-generated randomization list using variable block size.
3. Group A (n, 60, test group)will be received a low-calorie diet along with appropriate exercise counseling; and group B (n, 60, Control group) will be received balanced diet along with exercise advice.
Control Group
Subjects will be given routine care for diabetes and obesity management with no change in medication. The meal plan for the control group will consist of 1400 Kcal/day achieved through small frequently distributed meals constituting around 15% of protein, 60% of carbohydrates and 25% of fat; with a menu resembling standard Indian dietary patterns and meal combinations.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CURE-DM
1. This randomized controlled prospective trial will be of 2 years duration where 150 patients with T2DM from urban areas of Delhi will be screened.
2. These subjects will be randomized into two groups by computer-generated randomization list using variable block size.
3. Group A (n, 60, test group)will be received a low-calorie diet along with appropriate exercise counseling; and group B (n, 60, Control group) will be received balanced diet along with exercise advice.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 20-65 years
* BMI \>25-45kg/m2
* HbA1c\> 6.5% at baseline (on current treatment, if any)
Exclusion Criteria
* Weight loss of \>5 kg within the previous 6 months
* Significant cardiopulmonary
* Hepatic, or another endocrine disease
* Current participation in any other research drug study in the previous three months
* Past history of bariatric surgery Malignancy other than minor skin lesions and Possibility of pregnancy
20 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Science and Technology, India
OTHER_GOV
Diabetes Foundation, India
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-1312
Identifier Type: -
Identifier Source: org_study_id